Sunday 31 August 2014
 
»
 
»
Story

Boehringer, EFSD to fund diabetes research

Ingelheim (Germany), January 20, 2013

A new programme unveiled by Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and the European Foundation for the Study of Diabetes (EFSD) has invited European diabetes research projects to send in their applications to secure funding for their research work.

The research programmes will consider funding of basic research projects up to 100,000 euros ($133,521) in total for projects lasting up to 2 years, and clinical research projects up to 400,000 euros in total for projects up to 3 years in duration.

The diabetes partnership has opened submissions for diabetes research grant applications from across Europe, said a statement from Boehringer Ingelheim. The deadline for submissions is April 1 and the anticipated award date is June.

In a collaboration which aims to stimulate and accelerate European research in diabetes, the EFSD/BoehringerIngelheim European Diabetes Research Programmes have dedicated more than 2.5 million euros over three years to support research projects targeting specific areas of interest.

“Diabetes affects more than 371 million people worldwide and diabetes remains undiagnosed in up to 50 per cent of cases,” said Prof. Klaus Dugi, the corporate senior VP Medicine, BoehringerIngelheim.

“We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes,” he added.

The joint diabetes grant programme will focus on two areas of interest in order to achieve the goals and objectives of the programmes and will welcome proposals which target the following:
1. Regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas. (Basic research)
2. Mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes. (Clinical research)

“The EFSD is proud to collaborate once again with BoehringerIngelheim on this important research initiative,” said Dr Viktor Joergens, the executive director and vice director, EFSD.

“Ensuring sufficient funding for diabetes research in Europe is vital and we hope that this partnership leads the way to provide invaluable contributions to diabetes research,” he added.-TradeArabia News Service




Tags: Diabetes | Europe | Boehringer Ingelheim |

More Health & Environment Stories

calendarCalendar of Events

Ads